Welcome to the new KidsHealth website! See what is new.

Header

Low or no data? Visit zero.govt.nz, search for KidsHealth, and click on our logo to return and browse for free. Need help?

For free medical advice call Healthline 0800 611 116. Healthline provides a 24 hour, 7 days a week, over-the-phone health service. For emergencies call 111.  

On this page

Key points about 'opportunistic' infections and your child with cancer

  • if your child has a weakened immune system, they are at risk of developing infections caused by common germs that are usually harmless
  • one of the infections your child is at risk of developing is pneumocystis pneumonia
  • doctors can give your child medicine to reduce the risk of them developing pneumocystis pneumonia

Opportunistic infections

People who have a weakened immune system (infection-fighting system) are at risk of developing infections caused by common germs that are usually harmless. These infections are known as 'opportunistic'. This is because organisms that do not usually cause disease in healthy people use the opportunity created by lowered immunity to become infective.

Pneumocystis pneumonia

One opportunistic organism is a type of fungus called pneumocystis. This fungus can cause an infection called pneumocystis pneumonia (PCP).

Preventing pneumocystis pneumonia

Doctors can reduce the risk of your child with a weakened immune system developing pneumocystis pneumonia (PCP). They do this by giving your child medicine that helps prevent this infection from developing. This medicine will either be Cotrimoxazole or Pentamidine. 

Cotrimoxazole

Cotrimoxazole (also known as Bactrim) is an oral medicine that your child will take twice a day for 2 days a week, usually on a Saturday and Sunday.

Pentamidine

Pentamidine is an intravenous medicine that your child will have monthly, usually through a central line.

Acknowledgements

All the pages in the childhood cancer section of this website have been written by health professionals who work in the field of paediatric oncology. They have been reviewed by the members of the National Child Cancer Network (NZ). Medical information is authorised by the clinical leader of the National Child Cancer Network.

Last reviewed
Shielded site